Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06590961 · ClinicalTrials.gov registry record · Phase 1
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
A Phase 1 study of Relapsed/Refractory B-cell Malignancies, sponsored by Ubix Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 11
- Study locations
NCT06590961 is a Phase 1 study of Relapsed/Refractory B-cell Malignancies that is actively recruiting participants, run by Ubix Therapeutics. The registered enrollment target is 94 participants. The trial reports 11 study locations across 8 states.
The verdict
NCT06590961, a Phase 1 study of Relapsed/Refractory B-cell Malignancies, is actively recruiting participants, sponsored by Ubix Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
Conditions Studied
Interventions
- DRUG UBX-303061
Study Locations (11)
Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
- The Catholic University of Korea, Seoul St. Mary's Hospital - Seoul
- The Catholic University of Korea, Yeouido St. Mary's Hospital - Seoul
Michigan
- University of Michigan - Ann Arbor
Oklahoma
- Gabrail Cancer Center - Canton
Texas
- MD Anderson Cancer Center - Houston
Kuyavian-Pomeranian Voivodeship
- MICS Centrum Medyczne Toruń - Torun
Mazowieckie Voivodeship
- Pratia, MTZ Clinical Research - Warsaw
Silesian Voivodeship
- Pratia, Oncology Katowice - Katowice
Wielkopolskie Voivodeship
- AidPort - Grodzisk Wielkopolski
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2025-02-20 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06590961
The ClinicalTrials.gov registry entry for NCT06590961 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ubix Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory B-cell Malignancies appearing as the primary indexed condition, and to 1 intervention - of which UBX-303061 is the first listed.
NCT06590961 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Seoul, Michigan, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT06590961 about?
NCT06590961 is a clinical study titled "UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies". This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
What is the current status of trial NCT06590961?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2025-02-20. Estimated completion is 2027-08.
What conditions does trial NCT06590961 study?
This clinical trial studies the following conditions: Relapsed/Refractory B-cell Malignancies.
What interventions are being tested in trial NCT06590961?
The interventions under investigation include: UBX-303061 (DRUG).
Who is sponsoring clinical trial NCT06590961?
This trial is sponsored by Ubix Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06590961 being conducted?
This trial has 11 study locations across Michigan, Oklahoma, Texas, Kuyavian-Pomeranian Voivodeship, Mazowieckie Voivodeship. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory B-cell Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.